论文部分内容阅读
近年来,在市场上相同相似的中成药品种不少,相互竞争,为了扩大销售,采取各种手段,造成极为不好的影响。为此,笔者对如何扩大中成药生产品种的途径,谈了个人的看法。一、移植:凡是药典、部颁标准和地方标准上的品种,可以采用移植的途径试制报批就能投产。二、仿制:某些药厂科技信息和市场信息灵通,对别厂创新的疗效佳、销路畅的品种就赶紧仿照进行试制报批投产。其中有的原方照搬,有的是仿照创制。例如,安徽淮南市第一制药厂首创的小儿奇应丸,因销路畅,另几个厂很快就投入生产。梧州地区制药厂创制的健脾糖浆畅销各地,另一个药厂接着仿创了一个疗效和剂型相类似的脾康乐。这种途径,当独家创制品种还不能满足市场需要时,增加生产是可行的。但是,当生产的单位多,产值增大,易造成生产过剩,产品竞争力差。
In recent years, there are quite a few similar proprietary Chinese medicines in the market and they compete with each other. In order to expand sales, various methods are used, causing extremely bad influences. For this reason, the author discussed personal views on how to expand the ways of producing proprietary Chinese medicines. 1. Transplantation: All varieties in the pharmacopoeia, ministerial standards, and local standards can be put into production by trial-approval of the transplant method. Second, imitation: Some pharmaceutical companies have scientific and technological information and market information, and other plants have a good effect on the efficacy of innovation, and sales of a variety of species quickly rushed to trial production and approval. Some of them were copied, others were created. For example, the first children’s Qi Ying Pills in the first pharmaceutical factory in Huainan City, Anhui Province, were sold to other factories soon after being sold. The spleen syrup created by the pharmaceutical factory in Quzhou was sold well everywhere, and another pharmaceutical factory then created a spleen-like recreation with similar efficacy and dosage form. In this way, it is feasible to increase production when the exclusive product variety cannot meet market needs. However, when there are many production units and the output value increases, it will easily lead to overproduction and the products will be less competitive.